I-Idorsia Ltd. & Idorsia Pharmaceuticals, US Inc. namuhla imemezele ukuthi amaphilisi e-QUVIVIQ™ (daridoexant) CIV 25 mg kanye no-50 mg aseyatholakala ukuze athengiselwe iziguli ezikhulile ezinenkinga yokuqwasha, ebonakala ngenkinga yokuwa noma yokulala.
Ukuqwasha kuyisimo sokusebenza kobuchopho ngokweqile ngesikhathi sokulala, futhi ucwaningo luye lwabonisa ukuthi izindawo zobuchopho ezihlobene nokuphaphama zihlala zisebenza kakhulu phakathi nokulala ezigulini ezinokuqwasha. Ukuqwasha kuyisifo esivame kakhulu sokulala, esithinta abantu abadala abangaphezu kwezigidi ezingu-25 e-US.2 Ikhwalithi ephansi noma ukungalali ngokwanele kungathinta izici eziningi zokuphila kwansuku zonke kwabantu abanenkinga yokulala, kuhlanganise nekhono lokugxila, isimo sengqondo kanye namazinga wamandla.4 Esikhathini eside, ukuqwasha kuhlotshaniswa nezimo eziningi zempilo ezingathi sína, njengokuphazamiseka kwengqondo, isifo senhliziyo, ukusetshenziswa kabi kwezidakamizwa kanye nokuwohloka komqondo.5,6,7
I-QUVIVIQ iyi-dual orexin receptor antagonist, evimba ukuboshwa kwe-wake-promoting neuropeptides orexins futhi kucatshangwa ukuthi yehlisa ukuphaphama ngokweqile lapho uqwasha.3 I-QUVIVIQ inconywa kanye ngobusuku, ithathwe ngomlomo phakathi nemizuzu engu-30 ngaphambi kokulala, nge- okungenani amahora ayisikhombisa asele ngaphambi kokuvuka okuhleliwe.
U-Patricia Torr, uMongameli kanye neMenenja Jikelele yase-Idorsia US, ubeke amazwana:
“Ngemuva kweminyaka ezinikele ekucwaningeni ngesayensi yokulala nohlelo lwe-orexin, namuhla kuyingqophamlando e-Idorsia, njengoba umkhiqizo wokuqala wale nkampani e-US usuyatholakala ezigulini.”
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- “After years dedicated to researching the science of sleep and the orexin system, today is a momentous milestone for Idorsia, as the company’s first product in the US is now available to patients.
- Insomnia is a condition of overactive brain activity during sleep, and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia.
- QUVIVIQ is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness in insomnia.
